2022 Taihu Bay Future of Life & Health Conference Grandly Opens! Xidong New City CBD Makes a Strong Debut with Major Achievements!

Aug 05, 2022 14:42 CST Updated 14:42

On August 4, the 2022 Taihu Bay Life Health Future Conference, a prestigious professional event themed around the development of the life and health industry, grandly opened in Wuxi.

This conference has gathered over 100 renowned experts, scholars, industry leaders, and high-end resources from the life and health innovation ecosystem. It focuses on in-depth discussions about how the life and health industry can achieve innovative breakthroughs, surpass development expectations, and foster ecological integration, jointly exploring the future of life and health in the Taihu Bay region.

Honghui Fund, the cooperative fund of Xidong New City Business District, is one of the strategic partners of this conference. Wang Hui, Founder and CEO, engaged in a roundtable discussion with senior experts in the pharmaceutical industry on the topic of “Investment in the Life and Health Industry and Its Future.”

A series of signing and plaque-awarding ceremonies were held at the conference venue.

Three projects, namely the “Wuxi International Life and Health Industrial Park,” “Phase II of the Wuxi Precision Medicine Industrial Park,” and “Kejin Bio’s Gene Therapy Innovative Drug Project,” have completed signing in the Xidong New City Business District.

Wuxi Precision Medicine Industrial Park Awarded the Title of “Incubation Park for Wuxi Biopharmaceutical Industrial Parks” in 2022.

During the conference, Honghui Fund and the Xidong New City Business District jointly hosted the “Honghui Fund 2022 Annual CEO Summit.” Attendees included Zhou Wendong, Deputy Mayor of Wuxi City; Gu Wenhao and Lu Xiaobo, leaders of Xishan District; Meng Jingwei, a leader of the Business District; and heads of relevant departments. The summit attracted representatives from more than 50 ecosystem companies and over 60 investors from Honghui Fund.

Zhou Wendong, Vice Mayor of Wuxi City, stated in his address:

In recent years, seizing the window of opportunity presented by the explosive growth of the global biopharmaceutical industry, Wuxi has vigorously implemented its core innovation-driven strategy and its leading strategy for building a robust industrial city. It has prioritized the development of biopharmaceuticals as a landmark industry to secure a commanding position in development and build core competitiveness. After years of dedicated cultivation, Wuxi’s biopharmaceutical sector is witnessing unprecedented vitality in innovation and creation, with its industrial scale accelerating toward explosive growth.

Currently, Wuxi is accelerating the consolidation and enhancement of its “465” modern industrial system and striving to build the biopharmaceutical sector into a landmark industry. As never before, it urgently requires strong support from leading enterprises, including Honghui Capital. Hereby, I sincerely invite all the distinguished industry leaders and elites present to further support, increase investment in, and deepen their engagement with Wuxi.

Gu Wenhao, District Mayor of Xishan District, Wuxi City, stated in his address:

For a city to have a voice, its industries must occupy the strategic high ground. In the face of opportunities and challenges during the 14th Five-Year Plan period, Xishan District has focused on the “Four New and Four Strong” industrial directions, represented by biopharmaceuticals, adhering to the model of “industrial clusters + specialized parks” to vigorously promote industrial development to a higher level. Honghui Capital has maintained close cooperation with Xishan District, yielding fruitful results; multiple portfolio companies, including High Vision Medical, Kehui Zhiyao, and Borui New Drug, have successfully established operations in Xishan.

Today, the master plan for the Wuxi International Life and Health Industrial Park, developed in collaboration with Honghui Fund, is set to be released. By adopting a “Fund + Park” model to build an incubation system for medical innovation industries, we will undoubtedly achieve complementary advantages and resource sharing, continuing to write a brilliant chapter of “industry-finance integration and win-win development” between Xishan and Honghui Fund!

He Xing, Senior Managing Director of Honghui Fund, stated in his opening remarks:

Honghui Fund is an asset management company dedicated to driving technological innovation, leveraging deep industry insights as its core competency, empowering key sectors such as biopharmaceuticals and consumer livelihoods, and creating long-term value. Honghui Fund maintains strong relationships and in-depth cooperation with various districts in Wuxi. Notably, portfolio companies including HighSight Medical, Zhizhen Biologics, Kehui Zhiyao, Borui Medicine’s innovative drug headquarters, and Shicui Coffee have relocated their corporate headquarters to Wuxi, with total investments exceeding RMB 1 billion. It is believed that the continued development of the Wuxi Precision Medicine Industrial Park and the International Life and Health Industrial Park will attract more enterprises to Wuxi.

Honghui has established a robust investment portfolio across innovative biopharmaceuticals, precision medicine, medical devices, and consumer technology. We look forward to delivering an engaging and insightful discussion at this summit.

Wang Jiyan, Deputy Director of the Cuiping Mountain Tourism Resort Management Office and Director of the Business District Investment Promotion Bureau

Promoting the Wuxi Precision Medicine Industrial Park:

Wuxi Precision Medicine Industrial Park is a specialized biomedical park located in the city’s core area, offering convenient and comfortable living amenities. The park focuses on three key areas: First, in the field of precision diagnostics and health services, it prioritizes precision diagnostic services such as early cancer screening and companion diagnostics, complemented by proactive health management and medical consulting integrated with modern service industries. Second, in the realm of precision therapy, it emphasizes next-generation immunotherapeutic drugs, including cell therapies, gene therapies, and antibody-drug conjugates (ADCs), supported by contract research and development/manufacturing organizations (CRO/CDMO) platforms and AI-driven new drug discovery and development. Third, in the sector of high-end medical devices, it concentrates on high-value consumables such as implantable devices and ophthalmic and dental materials, in vitro diagnostic (IVD) reagents, and medical device manufacturing outsourcing platforms, supplemented by interventional devices and medical equipment.

Bole Enterprise Representative

Introduction to the Overall Planning of Wuxi International Life and Health Industrial Park：

Wuxi International Life and Health Industrial Park is a high-quality, next-generation model industrial park independently developed and operated by Jiangsu Bole Industrial Services, which provides comprehensive industrial services, with support from partners such as Honghui Capital. Located in the Xidong New City Business District of Xishan District, the Phase I site covers an area of approximately 47 mu, with a total gross floor area of about 51,000 square meters. The park focuses on industries including biopharmaceuticals, medical technology, health consumer tech, and deep tech. Integrating office, R&D, and production functions, the park also offers customized facility solutions tailored to enterprises’ specific needs, thereby accommodating the diverse requirements of tenant companies.

Subsequently, a secondary market exchange and sharing session was held by Haitong International, during which Luo Jiarong, Chief Pharmaceutical Analyst at GF Securities’ Research Department, delivered a presentation titled “Reflections on Innovative Drug Investment Under the New Landscape.”

At the summit, a special roundtable forum was held, themed “Challenges and Opportunities in the Development of Innovative Drugs,” “Application Trends and Prospects of Technology in the Consumer Sector,” and “Development Trends and Opportunities in the Pharmaceutical Industry and Supply Chain.” Leading figures from the investment and industrial sectors engaged in a brilliant peak dialogue.

In recent years, the business district has actively competed in the new track of the precision medicine industry. Leveraging leading enterprises in the field of precision diagnostics—such as Geneseeq, Yuanma Gene, and Biocore—the industrial chain for precision testing and medication guidance services has achieved an annual output value exceeding RMB 500 million and a valuation surpassing RMB 10 billion. The district has also attracted several emerging players in new drug R&D, including Borui Medicine, Kehui Zhiyao, and Kejin Biology, as well as multiple medical device companies such as Kuanyue Biology (focused on the R&D and production of knee and hip products), Shengya Medical (a supplier of breast ultrasound diagnosis + AI equipment), Weimai Qingtong (a supplier of minimally invasive energy ablation medical devices), and the headquarters of Gaoshi Medical, a leading domestic ophthalmic medical device company. Furthermore, the district has collaborated with Nanjing University to jointly establish the Nanjing University Wuxi Xishan Institute of Applied Biotechnology.